Abstracts tagged "Disease Activity"

Abstract Number: 2071 • 2013 ACR/ARHP Annual Meeting
Adipokines Contribute To The Inflammatory Response In Adult and Juvenile Myositis
Molly S. Hein¹, Cynthia S. Crowson², Helen Khun², Consuelo Lopez de Padilla³, Erik J. Peterson⁴, Emily Baechler⁵ and Ann M. Reed¹, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Department of Health Sciences Research, Mayo Clinic, Rochester, MN, ³Rheumatology/Immunology Research, Mayo Clinic, Rochester, MN, ⁴Medicine/Rheumatic and Autoimmune Diseases, University of Minnesota Medical School, Minneapolis, MN, ⁵Medicine, University of Minnesota, Minneapolis, MN
Background/Purpose: Recently adipokines have been implicated for their role in regulating immune and inflammatory responses in autoimmune disease. To test the hypothesis that adipokines are…
Abstract Number: 1528 • 2013 ACR/ARHP Annual Meeting
Patient-Tailored Dose Reduction Of Tumor Necrosis Factor-Alpha Blocking Agents In Ankylosing Spondylitis Patients With Stable Low Disease Activity
Suzanne Arends^1,2, Eveline van der Veer³, Fleur B.S. Kamps⁴, Monique Efde², Martha K. Leijsma⁴, Hendrika Bootsma¹, Elisabeth Brouwer⁵ and Anneke Spoorenberg^2,4, ¹Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands, ²Rheumatology, Medical Center Leeuwarden, Leeuwarden, Netherlands, ³Laboratory Medicine, University Medical Center Groningen, Groningen, Netherlands, ⁴Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, ⁵Dept. of Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands
Background/Purpose: Tumor necrosis factor-alpha (TNF-α) blocking agents are very effective in controlling inflammation and improving clinical assessments in patients with ankylosing spondylitis (AS). In view…
Abstract Number: 1323 • 2013 ACR/ARHP Annual Meeting
Plasma Leucine-Rich Alpha-2 Glycoprotein Is a Useful Disease Activity Biomarker In Rheumatoid Arthritis
Jung-Soo Song¹, You-Jung Ha², Eun-Jin Kang³, Kwang-Hoon Lee⁴, Sang-Won Lee⁵, Yong-Beom Park⁶, Soo-Kon Lee⁶ and Sang Tae Choi¹, ¹Rheumatology, Chung-Ang University College of Medicine, Seoul, South Korea, ²Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea, ³Rheumatology, Busan Medical Center, Busan, South Korea, ⁴Dongguk University Ilsan Hospital, Goyang, South Korea, ⁵Department of Internal Medicine, Yonsei University College of Medicine, Seoul, NV, South Korea, ⁶Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea
Background/Purpose: Leucine-rich a2-glycoprotein (LRG) is a plasma protein which contains leucine-rich repeats (LRRs). Though physiological functions of LRG have not been clarified yet, it has…
Abstract Number: 625 • 2013 ACR/ARHP Annual Meeting
Smoking and Secondhand Smoke Exposure Among Patients With Systemic Lupus Erythematosus and Controls: Associations With Disease and Disease Damage
Samantha J. Minkin, Stephanie N. Slan, Gary S. Gilkeson and Diane L. Kamen, Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, SC
Background/Purpose: Previous reports suggest smoking may be a risk factor for developing systemic lupus erythematosus (SLE), however the significance of this relationship varies among studies.…
Abstract Number: 2840 • 2013 ACR/ARHP Annual Meeting
Predictors Of Spinal Mobility Progression In A Multi-ethnic Cohort Of Patients With Ankylosing Spondylitis
Roozbeh Sharif¹, Trisha M. Parekh², Lianne S. Gensler³, MinJae Lee⁴, Mohammad Rahbar⁵, Laura A. Diekman⁶, Michael H. Weisman⁷, Michael M. Ward⁸, Shervin Assassi⁹ and John D. Reveille⁹, ¹Graduate School of Biomedical Science, University of Texas Medical Branch, Galveston, TX, ²Internal Medicine, University of Texas Medical Branch, Galveston, TX, ³Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ⁴Biostatistics/Epidemiology/Research Design (BERD) Core | Center for Clinical and Translational Sciences, University of Texas Health Science Center at Houston, Houston, TX, ⁵The University of Texas Health Science Center at Houston, Houston, TX, ⁶Rheumatology, The University of Texas Health Science Center at Houston, Houston, TX, ⁷Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁸Bldg 10 CRC Rm 4-1339, NIAMS/NIH, Bethesda, MD, ⁹Rheumatology, University of Texas Health Science Center at Houston, Houston, TX
Background/Purpose: Clinicians utilize several different clinical measurements (metrology) in patients with Ankylosing Spondylitis (AS) to assess the spinal mobility. We aimed to examine the pattern…
Abstract Number: 2356 • 2013 ACR/ARHP Annual Meeting
Soluble Interleukin-2 Receptor Levels and The CD4/CD8 Ratio As Predictors Of The Efficacy Of Abatacept In Biologics-naïve Rheumatoid Arthritis Patients
Hajime Sano¹, Masahiro Sekiguchi¹, Masayasu Kitano¹, Naoto Azuma¹, Shinichiro Tsunoda¹, Kiyoshi Matsui¹ and Tsuyoshi Iwasaki², ¹Division of Rheumatology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya-city, Japan, ²Department of Pharmacy, Hyogo University of Health Sciences, Kobe, Japan
Background/Purpose: Abatacept (ABT) is a recombinant fusion protein consisting of the extracellular domain of human CTLA-4, binding to CD80/86 on antigen presenting cells and thereby…
Abstract Number: 2083 • 2013 ACR/ARHP Annual Meeting
Environmental Factors Associated With Disease Flare In Juvenile and Adult Dermatomyositis
Gulnara Mamyrova¹, Lisa G. Rider², Olcay Jones³, Alison Ehrlich⁴, Lauren M. Pachman⁵, Robert Nickeson⁶, Lisa G. Criscione-Schreiber⁷, Frederick W. Miller², Lawrence K. Jung⁸ and James D. Katz¹, ¹Rheumatology, George Washington University, Washington, DC, ²Environmental Autoimmunity Group, NIEHS, NIH, Bethesda, MD, ³Pediatrics, Walter Reed National Military Medical Center, Bethesda, MD, ⁴Dermatology, The George Washington University, Washington, DC, ⁵Division of Pediatric Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁶Pediatrics, All Children's Hospital, St Petersburg, FL, ⁷Dept of Med/Rheum Div, Duke University School of Medicine, Durham, NC, ⁸Pediatric Rheumatology, Children's National Medical Center, Washington, DC
Background/Purpose: To assess environmental factors in relationship to increased disease activity (flare) in juvenile and adult dermatomyositis (DM). Methods: An online survey was conducted for…
Abstract Number: 1510 • 2013 ACR/ARHP Annual Meeting
Disease Activity In Male Smokers Has A >10-Fold Amplified Effect On Radiographic Damage In Comparison With Female NON-Smokers In Ankylosing Spondylitis
Sofia Ramiro^1,2, A.M. van Tubergen³, Robert Landewé⁴, Carmen Stolwijk⁵, Maxime Dougados⁶, Filip Van den Bosch⁷ and Désirée van der Heijde⁸, ¹Clinical Immunology & Rheumatology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, ²Rheumatology, Hospital Garcia de Orta, Almada, Portugal, ³Department of Internal Medicine, Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, ⁴Academic Medical Center Amsterdam & Atrium Medical Center, Heerlen, Netherlands, ⁵Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, ⁶Rheumatology B Department, Paris-Descartes University, Cochin Hospital, Paris, France, ⁷Ghent University Hospital, Ghent, Belgium, ⁸Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: We have shown that disease activity has an effect on radiographic progression over the long-term and that gender and symptom duration are effect modifiers.…
Abstract Number: 1329 • 2013 ACR/ARHP Annual Meeting
Physician Global Assessment At Three Months Is Strongly Predictive Of Remission At 12 Months In Early Rheumatoid Arthritis. Results From The Canadian Early Arthritis Cohort
Tommy Choy¹, Vivian P. Bykerk², Gilles Boire³, Boulos Haraoui⁴, Carol A. Hitchon⁵, J. Carter Thorne⁶, Edward C. Keystone⁷ and Janet E. Pope⁸, ¹Medicine/Rheumatology, University of Western Ontario, London, ON, Canada, ²Divison of Rheumatology, Hospital for Special Surgery, New York, NY, ³Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁴Rheumatology, Institut de Rhumatologie de Montréal, Montreal, QC, Canada, ⁵Rheumatology, University of Manitoba, Winnipeg, MB, Canada, ⁶Southlake Regional Health Centre, Newmarket, ON, Canada, ⁷Department of Medicine, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁸Medicine, Divsion of Rheumatology, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada
Background/Purpose: To determine predictors of 1-year remission in early rheumatoid arthritis (ERA) using baseline and 3 months data. Methods: The Canadian Early Arthritis Cohort (CATCH)…
Abstract Number: 642 • 2013 ACR/ARHP Annual Meeting
Serum Concentrations Of Type I Interferon-Regulated Chemokines Are Associated With Disease Activity In Systemic Lupus Erythematosus
Eric F. Morand, Kathryn Connelly and Alberta Y. Hoi, Centre for Inflammatory Diseases, Monash University, Melbourne, Australia
Background/Purpose: Expression array studies suggest the activity of Type I interferon (IFN), as reflected in IFN-induced genes, is associated with phenotypic subsets in SLE. Three…
Abstract Number: 2811 • 2013 ACR/ARHP Annual Meeting
Disease Characteristics and Treatment Patterns In US Veterans With Rheumatoid Arthritis and Concomitant Hepatitis C Infection
Ruchika Patel¹ and Joshua Baker², ¹Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Medicine/Rheumatology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: The prevalence of concurrent rheumatoid arthritis (RA) and hepatitis C (HCV) is estimated at 0.02%, affecting around 40,000 Americans. To our knowledge, no existing…
Abstract Number: 2341 • 2013 ACR/ARHP Annual Meeting
Efficacy Of Adalimumab Plus Methotrexate Therapy In Rheumatoid Arthritis Non-Responders Receiving Methotrexate Monotherapy Or Adalimumab Combination Therapy: Results From The Optima Trial
Josef S. Smolen¹, Ronald F. van Vollenhoven², Roy Fleischmann³, Paul Emery⁴, Stefan Florentinus⁵, Suchitrita S. Rathmann⁶, Anabela Cardoso⁷, Hartmut Kupper⁸ and Arthur Kavanaugh⁹, ¹Medical University of Vienna and Hietzing Hospital, Vienna, Austria, ²The Karolinska Institute, Stockholm, Sweden, ³University of Texas Southwestern Medical Center, Dallas, TX, ⁴Leeds Teaching Hospital, Leeds, United Kingdom, ⁵AbbVie, Rungis, France, ⁶AbbVie Inc., North Chicago, IL, ⁷AbbVie, Amadora, Portugal, ⁸AbbVie Deutschland GmBH & Co. KG, Ludwigshafen, Germany, ⁹University of California, San Diego, La Jolla, CA
Background/Purpose: EULAR recommendations advocate Methotrexate (MTX) as first line therapy. For patients (pts) who fail to attain remission or low disease activity (LDA) after 6…
Abstract Number: 1930 • 2013 ACR/ARHP Annual Meeting
Patients’ Response To a Sleep Question and Disease Activity In Multiple Rheumatic Conditions
Sapna Sangani¹ and Martin J. Bergman², ¹Medicine, Mercy Catholic Medical Center, Lansdowne, PA, ²Medicine, Drexel University College of Medicine, Philadelphia, PA
Patient's Response To A Sleep Question And Disease Activity Levels In Multiple Rheumatic ConditionsBackground/Purpose: Sleep disturbances can have an impact on the quality of life…
Abstract Number: 1511 • 2013 ACR/ARHP Annual Meeting
What Impairs Balance In Ankylosing Spondylitis? Posture Or Disease Activity?
Osman Hakan Gunduz¹, Emel Ece Ozcan¹, Esra Giray¹ and Ilker Yagci², ¹Physical Medicine and Rehabilitation, Marmara University School of Medicine, Istanbul, Turkey, ²Department of Physical Medicine and Rehabilitation, Marmara University School of Medicine, Istanbul, Turkey
Background/Purpose: To compare ankylosing spondylitis (AS) patients and healthy individuals in terms of posture and balance and to identify the factors affecting balance among patients…
Abstract Number: 1301 • 2013 ACR/ARHP Annual Meeting
The Tumor Necrosis Factor Stimulated Gene-6 Promoter Reporter Can Monitor The Disease Activity In Rheumatoid Arthritis
Mathijs G.A. Broeren¹, Eline A. Vermeij¹, Onno J. Arntz², Miranda B. Bennink¹, Emma Sterken¹, Calin Popa², Tim L. Jansen³, Wim B. van den Berg⁴ and Fons A.J. Van de Loo⁵, ¹Rheumatology Research and Advanced Therapeutics, Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ²Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ³Rheumatology, Radboud UMC, Nijmegen, Netherlands, ⁴Experimental Rheumatology (272), Radboud university medical center, Nijmegen, Netherlands, ⁵Rheumatology Research and Advanced Therapeutics, Rheumatology Research and Advanced Therapeutics, Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
Background/Purpose: An important step in the optimal personalized treatment of rheumatoid arthritis (RA) patients, is the accurate assessment of disease activity, disease progression and therapy…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].